219763-06-1

Basic information

• Product Name: 2-METHYL-BENZOFURAN-5-CARBOXYLIC ACID
• Synonyms: 2-METHYL-BENZOFURAN-5-CARBOXYLIC ACID;2-METHYL-1-BENZOFURAN-5-CARBOXYLIC ACID;CHEMBRDG-BB 4013749;Albb-005576;2-methyl-1-benzofuran-5-carboxylic acid(SALTDATA: FREE);2-methyl-5-benzofurancarboxylic acid
• CAS NO: 219763-06-1
• Molecular Formula: C10H8O3
• Molecular Weight: 176.17
• Mol File: 219763-06-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 342.7°C at 760 mmHg
• Flash Point: 161.1°C
• Appearance: /
• Density: 1.303g/cm³
• Vapor Pressure: 2.84E-05mmHg at 25°C
• Refractive Index: 1.631
• CAS DataBase Reference: 2-METHYL-BENZOFURAN-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-BENZOFURAN-5-CARBOXYLIC ACID(219763-06-1)
• EPA Substance Registry System: 2-METHYL-BENZOFURAN-5-CARBOXYLIC ACID(219763-06-1)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 219763-06-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H8O3/c1-6-4-8-5-7(10(11)12)2-3-9(8)13-6/h2-5H,1H3,(H,11,12)

Upstream product

• 25016-01-7 5-bromo-2-methoxybenzaldehyde 
• 54965-04-7 5-bromo-2-methylbenzo[b]furan 
• 124-38-9 carbon dioxide 
• 1761-61-1 5-bromosalicyclaldehyde 
• 117379-97-2 5-methoxycarbonyl-2-methylbenzofuran 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 35750-24-4 methyl 4-allyloxybenzoate 
• 16238-12-3 2-methylbenzofuran-5-carbonitrile 
• 588702-92-5 methyl-2-trimethylsilylmethyl-benzofuran-5-carboxylate 
• 74-88-4 methyl iodide 
• 15804-76-9 3-(2-nitropropen-1-yl)-4-methoxybromobenzene 
• 205826-73-9 (5-Bromo-2-methoxyphenyl)acetone 
• 53596-60-4 methyl 3-allyl-4-hydroxybenzoate 

Downstream Products

• 117379-97-2 5-methoxycarbonyl-2-methylbenzofuran 
• 219764-11-1 3-(4-bromo-2-chlorobenzyl)-5-(methoxycarbonyl)-2-methylbenzo[b]furan 
• 219763-10-7 5-carboxy-3-(2,4-dichlorobenzyl)-2-methylbenzo[b]furan 
• 219764-14-4 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylbenzo[b]furan 
• 219763-07-2 3-(2,4-Dichlorobenzoyl)-5-(methoxycarbonyl)-2-methylbenzo[b]furan 
• 219763-17-4 5-carboxy-2-methyl-3-(4-phenylbenzyl)benzo[b]furan 

Relevant articles and documents

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.